Trials / Enrolling By Invitation
Enrolling By InvitationNCT06540144
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
An Open-label Extension Study to Evaluate Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
- Status
- Enrolling By Invitation
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the long term safety and tolerability of additional 6-week treatment cycles with rozanolixizumab in pediatric participants with generalized Myasthenia Gravis (gMG) aged ≥2 at the time of the Screening Visit of MG0006.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rozanolixizumab | rozanolixizumab solution for injection |
Timeline
- Start date
- 2024-10-08
- Primary completion
- 2027-08-17
- Completion
- 2027-08-17
- First posted
- 2024-08-06
- Last updated
- 2026-04-13
Locations
10 sites across 4 countries: Italy, Japan, Poland, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06540144. Inclusion in this directory is not an endorsement.